Davuluri Ownership Trust has submitted its annual compliance certificate to stock exchanges for the financial year ended March 31, 2026, confirming adherence to regulatory requirements under a SEBI exemption order. The trust, led by Trustee Dr. Davuluri Rama Mohan Rao, filed the certificate with both BSE Limited and The National Stock Exchange of India Limited on April 9, 2026.

Regulatory Compliance Framework

The compliance certificate was issued pursuant to SEBI Exemption Order No. WTM/ASB/CFD/17/2024-25 dated January 3, 2025, read with regulation 11 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The submission relates to the trust's shareholding in Neuland Laboratories Limited, which trades under scrip codes 524558 on BSE and NEULANDLAB on NSE.

Independent Audit Verification

The compliance certificate was issued by B Srinivasa Rao & Co., Chartered Accountants, who served as independent auditors to verify the trust's compliance status. CA Ranga Rai Chowdary M, Partner with membership number 243733, signed the certificate on April 7, 2026, from the firm's Hyderabad office.

The audit scope encompassed verification of compliance with:

• Conditions specified in the SEBI exemption order
• Disclosure and governance requirements under SEBI SAST Regulations
• Trust deed provisions and related documentation
• Necessary disclosures to stock exchanges and SEBI

Auditor's Assessment and Opinion

The independent auditors conducted their examination in accordance with guidance notes issued by the Institute of Chartered Accountants of India for special purpose reports. They confirmed compliance with ethical requirements and quality control standards applicable to audit engagements.

Based on their examination of relevant records and information provided, the auditors certified that Davuluri Ownership Trust complied with all conditions stipulated in the SEBI exemption order and applicable SAST regulation provisions for the year ended March 31, 2026.

Regulatory Framework and Limitations

The trust's management holds responsibility for ensuring compliance with applicable SEBI regulations and maintaining proper accounting and supporting records. This includes designing and implementing internal controls relevant to regulatory compliance and providing necessary information to SEBI as required.

The auditors noted that their certificate was issued solely for submission to SEBI and stock exchanges under the aforementioned order and should not be used for any other purpose. The compliance certificate was also copied to SEBI's Mumbai office and the Company Secretary of Neuland Laboratories Limited in Hyderabad, ensuring all relevant regulatory bodies and the target company were informed of the trust's continued compliance status.

Neuland Laboratories Limited has completed its regulatory filing requirements by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed this compliance certificate on April 2, 2026, ensuring adherence to securities market regulations.

Regulatory Filing Details

The certificate was formally submitted to both major Indian stock exchanges where the company's shares are traded. Company Secretary Sarada Bhamidipati signed the submission letter on behalf of Neuland Laboratories Limited, addressing the filing to BSE Limited and The National Stock Exchange of India Ltd.

Registrar and Transfer Agent Certification

KFin Technologies Limited, serving as the company's Registrar and Share Transfer Agent, provided the necessary certification for this regulatory requirement. Senior Vice President Praveen Chaturvedi signed the certificates on April 1, 2026, confirming compliance with SEBI regulations.

The registrar issued separate certificates to both Central Depository Services (India) Limited (CDSL) and National Securities Depository Limited (NSDL), the two main depositories in India. These certificates confirm that all required details of securities dematerialized and rematerialized during the quarter have been properly furnished to the relevant stock exchanges.

Compliance Confirmation

The certification process ensures transparency in the dematerialization and rematerialization of securities during the specified quarter. KFin Technologies Limited certified that all necessary details regarding these transactions have been appropriately communicated to the stock exchanges where Neuland Laboratories' shares are listed.

This regulatory filing represents standard compliance practice for listed companies in India, ensuring proper documentation and reporting of securities transactions to maintain market transparency and investor protection.